Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management

Abstract

Platelet transfusion refractoriness due to HLA alloimmunization presents a significant medical problem, particularly among multiply transfused patients with hematologic malignancies and those undergoing hematopoietic stem cell transplants. HLA compatible platelet transfusions also impose significant financial burden on these patients. Recently, several novel mechanisms have been described in the development of HLA alloimmunization and platelet transfusion refractoriness. We review the history of platelet transfusions and mechanisms of HLA-sensitization and transfusion refractoriness. We also summarize advances in the diagnosis and treatment of platelet transfusion refractoriness due to HLA alloimmunization.

Keywords: Alloimmunization; HLA; HPA; Human leukocyte antigen; Immune platelet destruction; Leukemia; MFI; Platelet transfusion; Platelet transfusion refractoriness; Platelets; Stem cell transplantation.